400 related articles for article (PubMed ID: 27918201)
1. The importance of treating by histological subtype in advanced soft tissue sarcoma.
Martín Broto J; Le Cesne A; Reichardt P
Future Oncol; 2017 Jan; 13(1s):23-31. PubMed ID: 27918201
[TBL] [Abstract][Full Text] [Related]
2. Protocol for the 2ND-STEP study, Japan Clinical Oncology Group study JCOG1802: a randomized phase II trial of second-line treatment for advanced soft tissue sarcoma comparing trabectedin, eribulin and pazopanib.
Endo M; Kataoka T; Fujiwara T; Tsukushi S; Takahashi M; Kobayashi E; Yamada Y; Tanaka T; Nezu Y; Hiraga H; Wasa J; Nagano A; Nakano K; Nakayama R; Hamada T; Kawano M; Torigoe T; Sakamoto A; Asanuma K; Morii T; Machida R; Sekino Y; Fukuda H; Oda Y; Ozaki T; Tanaka K
BMC Cancer; 2023 Mar; 23(1):219. PubMed ID: 36890471
[TBL] [Abstract][Full Text] [Related]
3. Soft tissue sarcomas, a look into the future: different treatments for different subtypes.
Reichardt P
Future Oncol; 2014 Jun; 10(8 Suppl):s19-27. PubMed ID: 25048045
[TBL] [Abstract][Full Text] [Related]
4. Getting up-to-date in the management of soft tissue sarcoma.
Blay JY
Future Oncol; 2018 May; 14(10s):3-13. PubMed ID: 29768050
[TBL] [Abstract][Full Text] [Related]
5. Options for treating different soft tissue sarcoma subtypes.
Ray-Coquard I; Serre D; Reichardt P; Martín-Broto J; Bauer S
Future Oncol; 2018 May; 14(10s):25-49. PubMed ID: 29768052
[TBL] [Abstract][Full Text] [Related]
6. Soft tissue sarcomas.
Spiguel A
Cancer Treat Res; 2014; 162():203-23. PubMed ID: 25070237
[TBL] [Abstract][Full Text] [Related]
7. Oncological outcome of patients with deeply located soft tissue sarcoma of the pelvis: a follow up study at minimum 5 years after diagnosis.
Nakamura T; Abudu A; Murata H; Grimer RJ; Carter SR; Tillman RM; Jeys L
Eur J Surg Oncol; 2013 Sep; 39(9):1030-5. PubMed ID: 23347778
[TBL] [Abstract][Full Text] [Related]
8. The clinical outcome of pazopanib treatment in Japanese patients with relapsed soft tissue sarcoma: A Japanese Musculoskeletal Oncology Group (JMOG) study.
Nakamura T; Matsumine A; Kawai A; Araki N; Goto T; Yonemoto T; Sugiura H; Nishida Y; Hiraga H; Honoki K; Yasuda T; Boku S; Sudo A; Ueda T
Cancer; 2016 May; 122(9):1408-16. PubMed ID: 26970174
[TBL] [Abstract][Full Text] [Related]
9. [Histology-Specific Chemotherapy in Soft-Tissue Sarcomas].
Kobayashi E; Kawai A
Gan To Kagaku Ryoho; 2017 Jun; 44(6):468-472. PubMed ID: 28698435
[TBL] [Abstract][Full Text] [Related]
10. Prognostic and predictive factors for outcome to first-line ifosfamide-containing chemotherapy for adult patients with advanced soft tissue sarcomas: an exploratory, retrospective analysis on large series from the European Organization for Research and Treatment of Cancer-Soft Tissue and Bone Sarcoma Group (EORTC-STBSG).
Sleijfer S; Ouali M; van Glabbeke M; Krarup-Hansen A; Rodenhuis S; Le Cesne A; Hogendoorn PC; Verweij J; Blay JY
Eur J Cancer; 2010 Jan; 46(1):72-83. PubMed ID: 19853437
[TBL] [Abstract][Full Text] [Related]
11. Treatment of soft tissue sarcoma: a focus on earlier stages.
Gronchi A; Maki RG; Jones RL
Future Oncol; 2017 Jan; 13(1s):13-21. PubMed ID: 27918202
[TBL] [Abstract][Full Text] [Related]
12. Contemporary management of metastatic soft tissue sarcoma.
Bui NQ; Wang DS; Hiniker SM
Curr Probl Cancer; 2019 Aug; 43(4):289-299. PubMed ID: 31248634
[TBL] [Abstract][Full Text] [Related]
13. Treatment of advanced soft tissue sarcoma by histological subtype: wish, prediction or reality?
Blay JY
Future Oncol; 2019 Sep; 15(26s):5-10. PubMed ID: 31500446
[TBL] [Abstract][Full Text] [Related]
14. Emerging therapies for adult soft tissue sarcoma.
Radaelli S; Stacchiotti S; Casali PG; Gronchi A
Expert Rev Anticancer Ther; 2014 Jun; 14(6):689-704. PubMed ID: 24555529
[TBL] [Abstract][Full Text] [Related]
15. Systemic Therapy for Soft Tissue Sarcoma: Proposals for the Optimal Use of Pazopanib, Trabectedin, and Eribulin.
Kawai A; Yonemori K; Takahashi S; Araki N; Ueda T
Adv Ther; 2017 Jul; 34(7):1556-1571. PubMed ID: 28547734
[TBL] [Abstract][Full Text] [Related]
16. Treatment of advanced soft tissue sarcoma: efficacy and safety of trabectedin, a multitarget agent, and update on other systemic therapeutic options.
Duffaud F; Maki RG; Jones RL
Expert Rev Clin Pharmacol; 2016 Apr; 9(4):501-512. PubMed ID: 26873304
[TBL] [Abstract][Full Text] [Related]
17. Advances and controversies in the management of soft tissue sarcomas.
Demetri GD; Blay JY; Casali PG
Future Oncol; 2017 Jan; 13(1s):3-11. PubMed ID: 27918199
[TBL] [Abstract][Full Text] [Related]
18. Established and Experimental Systemic Treatment Options for Advanced Liposarcoma.
Schöffski P
Oncol Res Treat; 2022; 45(9):525-543. PubMed ID: 35609512
[TBL] [Abstract][Full Text] [Related]
19. Efficacy of trabectedin in advanced soft tissue sarcoma: beyond lipo- and leiomyosarcoma.
De Sanctis R; Marrari A; Marchetti S; Mussi C; Balzarini L; Lutman FR; Daolio P; Bastoni S; Bertuzzi AF; Quagliuolo V; Santoro A
Drug Des Devel Ther; 2015; 9():5785-91. PubMed ID: 26604682
[TBL] [Abstract][Full Text] [Related]
20. T-cell infiltration and clonality correlate with programmed cell death protein 1 and programmed death-ligand 1 expression in patients with soft tissue sarcomas.
Pollack SM; He Q; Yearley JH; Emerson R; Vignali M; Zhang Y; Redman MW; Baker KK; Cooper S; Donahue B; Loggers ET; Cranmer LD; Spraker MB; Seo YD; Pillarisetty VG; Ricciotti RW; Hoch BL; McClanahan TK; Murphy E; Blumenschein WM; Townson SM; Benzeno S; Riddell SR; Jones RL
Cancer; 2017 Sep; 123(17):3291-3304. PubMed ID: 28463396
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]